Earnings Call Summary | BioCardia(BCDA.US) Q4 2023 Earnings Conference
Earnings Call Summary | BioCardia(BCDA.US) Q4 2023 Earnings Conference
The following is a summary of the BioCardia, Inc. (BCDA) Q4 2023 Earnings Call Transcript:
以下是BioCardia, Inc.（BCDA）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
BioCardia's revenues fell to $0.5 million in 2023 from $1.4 million in the previous year, primarily due to the timing of revenue recognition from its collaboration partners.
Expenses decreased by 9% with significant savings in research and development expenditure, which dropped to $7.7 million in 2023 from $8.8 million in 2022.
2023 ended with a net loss of $11.6 million, slightly less than the $11.9 million net loss in 2022.
BioCardia had $1.1 million in cash by the end of 2023, sufficient to sustain operations until Q2 2024.
BioCardia的收入從去年的140萬美元降至2023年的50萬美元，這主要是由於其合作伙伴確認收入的時機所致。
支出下降了9％，研發支出大幅減少，從2022年的880萬美元降至2023年的770萬美元。
2023年結束時淨虧損1160萬美元，略低於2022年的1190萬美元淨虧損。
到2023年底，BioCardia擁有110萬澳元的現金，足以維持運營至2024年第二季度。
Business Progress:
業務進展：
BioCardia displayed promising development of lead CardiAMP autologous cell therapy for treating ischemic heart failure.
Despite missing the primary pre-specified endpoint in the Cardiac Heart Failure clinical trial, the results supported the continuation of the program.
BioCardia is also advancing with the CardiAMP Heart Failure II study, the CardiAMP cell therapy trial for chronic myocardial ischemia (BCDA-02), and a partnership with StemCardia.
The company has shifted its Helix Biotherapeutic Delivery Partnering Business to focus on longer-term partnerships, planning to have two additional partners in 2024.
BioCardia aims to broaden the FDA-cleared Helix system and Morph DNA platform to cover cardiac and peripheral vascular disease indications.
It has recorded an encouraging reduction in cardiac arrhythmias in the BCDA-01 trial's interim data and plans to pre-specify this as a secondary endpoint in future trials.
Expansion in the CardiAMP Heart Failure II confirmatory study and consultations with Japan's PMDA remain high on the agenda.
With five cardiac biotherapeutic programs in development, BioCardia is on track to continue its mission of addressing heart disease.
BioCardia展示了治療缺血性心力衰竭的先導CardiAMP自體細胞療法的發展前景。
儘管在心臟心力衰竭臨床試驗中沒有達到預先規定的主要終點，但結果支持了該計劃的延續。
BioCardia還在推進Cardiamp心力衰竭II研究、針對慢性心肌缺血的Cardiamp細胞療法試驗（BCDA-02）以及與Stemcardia的合作。
該公司已將其Helix生物治療交付合作業務轉向長期合作伙伴關係，並計劃在2024年再增加兩個合作伙伴。
BioCardia旨在擴大經美國食品藥品管理局批准的Helix系統和Morph DNA平台，以涵蓋心臟和外周血管疾病的適應症。
它在 BCDA-01 試驗的中期數據中記錄了令人鼓舞的心律失常的減少，並計劃在未來的試驗中將其預先指定爲次要終點。
擴大Cardiamp心力衰竭II確認性研究以及與日本PMDA的磋商仍然是議程的重中之重。
隨着五項心臟生物治療項目正在開發中，BioCardia有望繼續其解決心臟病的使命。
More details: BioCardia IR
更多詳情： BioCardia IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。